PharmaCyte Biotech, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 56.5K | $37.59K | 0.00% | Trimmed-39.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2022-09-14 | -0.07 | -0.07 | — |
| 2022-07-28 | -0.04 | -0.06 | -50.00% |
| 2022-03-15 | -0.05 | -0.04 | +20.00% |
| 2021-12-14 | -0.07 | -0.06 | +14.29% |
| 2015-08-25 | -15.00 | — | +100.00% |
| 2015-07-29 | -15.00 | -15.00 | — |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PMCB | +10.47% | +20.44% | +15.25% | -22.02% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | +7.50% | +25.27% | +18.69% | -34.64% |